Login Register Cart 0
Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Concomitant use of Tyrosine-Kinase Inhibitor and Mepolizumab in Asthma Secondary to Chronic Myeloid Leukemia with Hypereosinophilia

Author(s): Antonio Gidaro*, Emanuele Salvi, Maria Cristina Carraro, Roberta Simona Rossi and Roberto Castelli

Volume 20, Issue 4, 2021

Published on: 20 August, 2021

Page: [389 - 393] Pages: 5

DOI: 10.2174/1871523020999210820091109

Price: $65

Open Access Journals Promotions 2
Abstract

Introduction: Asthma and hypereosinophilia have been treated with different therapeutics in the past. Some of them appear to be more effective in symptoms resolution and decreasing eosinophilic count.

Case Presentation: We report here an unusual case of asthma with hypereosinophilia secondary to Chronic Myeloid Leukemia (CML) with high prevalence of eosinophilic infiltrate, treated simultaneously with an anti-IL-5 antibody (Mepolizumab) and Tyrosine-kinase Inhibitors (TKI: Imatinib and Bosutinib) for three years. The patient showed a promising reduction of pulmonary exacerbations and good control of CML without developing side effects.

Conclusion: We hope that this finding could inspire further studies on the efficacy and safety of the concomitant use of anti-IL-5 and TKI.

Keywords: Asthma, chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKI), mepolizumab, hypereosinophilia (HE), eosinophilic count.

« Previous Next »
Graphical Abstract

[1]
Noh, H.R.; Magpantay, G.G. Hypereosinophilic syndrome. Allergy Asthma Proc., 2017, 38(1), 78-81.
[http://dx.doi.org/10.2500/aap.2017.38.3995] [PMID: 28052805]
[2]
Saglio, G.; Jabbour, E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk. Lymphoma, 2018, 59(7), 1523-1538.
[http://dx.doi.org/10.1080/10428194.2017.1379074] [PMID: 28972424]
[3]
Gul, A.; Rini, B.I. Adjuvant therapy in renal cell carcinoma. Cancer, 2019, 125(17), 2935-2944.
[http://dx.doi.org/10.1002/cncr.32144] [PMID: 31225907]
[4]
von Mehren, M.; Joensuu, H. Gastrointestinal Stromal Tumors. J. Clin. Oncol., 2018, 36(2), 136-143.
[http://dx.doi.org/10.1200/JCO.2017.74.9705] [PMID: 29220298]
[5]
Ceolin, L.; Duval, M.A.D.S.; Benini, A.F.; Ferreira, C.V.; Maia, A.L. Medullary thyroid carcinoma beyond surgery: Advances, challenges, and perspectives. Endocr. Relat. Cancer, 2019, 26(9), R499-R518.
[http://dx.doi.org/10.1530/ERC-18-0574] [PMID: 31252403]
[6]
Liao, B.C.; Lin, C.C.; Lee, J.H.; Yang, J.C. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer, 2017, 110, 7-13.
[http://dx.doi.org/10.1016/j.lungcan.2017.05.009] [PMID: 28676222]
[7]
Klion, A. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine. Hematology (Am. Soc. Hematol. Educ. Program), 2018, 2018(1), 326-331.
[http://dx.doi.org/10.1182/asheducation-2018.1.326] [PMID: 30504328]
[8]
Stella, S.; Massimino, M.; Manzella, L.; Pennisi, M.S.; Tirrò, E.; Romano, C.; Vitale, S.R.; Puma, A.; Tomarchio, C.; Gregorio, S.D.; Palumbo, G.A.; Vigneri, P. Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes. Int. J. Mol. Sci., 2021, 22(2), 486.
[http://dx.doi.org/10.3390/ijms22020486] [PMID: 33418988]
[9]
Colice, G.L. Emerging therapeutic options for asthma. Am. J. Manag. Care, 2011, 17(3), S82-S89.
[PMID: 21761958]
[10]
Claudiani, S.; Apperley, J.F. The argument for using imatinib in CML. Hematology (Am. Soc. Hematol. Educ. Program), 2018, 2018(1), 161-167.
[http://dx.doi.org/10.1182/asheducation-2018.1.161] [PMID: 30504305]
[11]
Cortes, J.E.; Kantarjian, H.M.; Brümmendorf, T.H.; Kim, D.W.; Turkina, A.G.; Shen, Z.X.; Pasquini, R.; Khoury, H.J.; Arkin, S.; Volkert, A.; Besson, N.; Abbas, R.; Wang, J.; Leip, E.; Gambacorti-Passerini, C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 2011, 118(17), 4567-4576.
[http://dx.doi.org/10.1182/blood-2011-05-355594] [PMID: 21865346]
[12]
Puttini, M.; Coluccia, A.M.; Boschelli, F.; Cleris, L.; Marchesi, E.; Donella-Deana, A.; Ahmed, S.; Redaelli, S.; Piazza, R.; Magistroni, V.; Andreoni, F.; Scapozza, L.; Formelli, F.; Gambacorti- Passerini, C. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res., 2006, 66(23), 11314-11322.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1199] [PMID: 17114238]
[13]
Khoury, P.; Abiodun, A.O.; Holland-Thomas, N.; Fay, M.P.; Klion, A.D. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids. J. Allergy Clin. Immunol. Pract., 2018, 6(1), 190-195.
[http://dx.doi.org/10.1016/j.jaip.2017.06.006] [PMID: 28757367]
[14]
Sreedharanunni, S; Varma, N; Sachdeva, MUS The spectrum of hypereosinophilia and associated clonal disorders - a real-world data based on combined retrospective and prospective analysis from a tropical setting. Mediterr. J. Hematol. Infect. Dis., 2018, 10(1), e2018052.
[http://dx.doi.org/10.4084/mjhid.2018.052]
[15]
Hasford, J.; Pfirrmann, M.; Hehlmann, R.; Allan, N.C.; Baccarani, M.; Kluin-Nelemans, J.C.; Alimena, G.; Steegmann, J.L.; Ansari, H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J. Natl. Cancer Inst., 1998, 90(11), 850-858.
[http://dx.doi.org/10.1093/jnci/90.11.850] [PMID: 9625174]
[16]
Hassani, M.; Koenderman, L. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview. Allergy, 2018, 73(10), 1979-1988.
[http://dx.doi.org/10.1111/all.13451] [PMID: 29611207]
[17]
Abbas, R.; Hsyu, P.H. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clin. Pharmacokinet., 2016, 55(10), 1191-1204.
[http://dx.doi.org/10.1007/s40262-016-0391-6] [PMID: 27113346]
[18]
Abbas, A.; Mirza, M.M.; Ganti, A.K.; Tendulkar, K. Renal toxicities of targeted therapies. Target. Oncol., 2015, 10(4), 487-499.
[http://dx.doi.org/10.1007/s11523-015-0368-7] [PMID: 25922090]
[19]
Lopina, N.; Dmytrenko, I.; Hamov, D.; Lopin, D.; Dyagil, I. Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic imatinib-induced liver injury. Cureus, 2019, 11(4), e4411.
[http://dx.doi.org/10.7759/cureus.4411] [PMID: 31245199]
[20]
Roufosse, F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med. (Lausanne), 2018, 5, 49.
[http://dx.doi.org/10.3389/fmed.2018.00049]
[21]
Koury, M.J.; Newman, J.H.; Murray, J.J. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am. J. Med., 2003, 115(7), 587-589.
[http://dx.doi.org/10.1016/S0002-9343(03)00475-3] [PMID: 14599646]

Rights & Permissions Print Cite
Article Metrics
34
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy